edotreotide has been researched along with Kidney Failure in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apostolidis, C; Apostolidis, L; Bicu, F; Bruchertseifer, F; Choyke, PL; Giesel, FL; Haberkorn, U; Kratochwil, C; Morgenstern, A; Rathke, H | 1 |
| Bartolomei, M; Bodei, L; Caracciolo, M; Chinol, M; Cremonesi, M; Grana, C; Mäcke, HR; Paganelli, G; Rocca, P; Zoboli, S | 1 |
1 trial(s) available for edotreotide and Kidney Failure
| Article | Year |
|---|---|
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Topics: Adult; Aged; Amino Acids; Biomarkers, Tumor; Blood Platelets; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hemoglobins; Humans; Kidney; Lymphocytes; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Octreotide; Radiation-Protective Agents; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Renal Insufficiency; Vomiting; Yttrium Radioisotopes | 2003 |
1 other study(ies) available for edotreotide and Kidney Failure
| Article | Year |
|---|---|
Dosing
Topics: Follow-Up Studies; Humans; Neuroendocrine Tumors; Octreotide; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Renal Insufficiency; Retrospective Studies; Somatostatin; Tomography, X-Ray Computed | 2021 |